The BMT and CCT teams celebrated 2 successful FDA audits (in April and July 2017) and recent approvals of Ibrutinib for steroid-refractory/steroid dependent patients with cGVHD and Yescarta for diffuse large b-cell lymphoma (DLBCL) (the second FDA approved gene therapy) with a sailing trip around the SF Bay followed by dinner in San Francisco. Congratulations to these teams for such great accomplishments and a wonderful celebration!